HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus

HONG KONG, Oct 31, 2025 - (ACN Newswire via SeaPRwire.com) – HighTide Therapeutics, Inc. (2511.HK), a biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic metabolic diseases, announced positive 52-week safety and efficacy results from the open-label extension (OLE) phases of two Phase III trials (SYMPHONY-1 and SYMPHONY-2)…

MHI and Nippon Shokubai to Develop Ammonia Cracking System for NEDO’s “Development of Technologies for Building a Competitive Hydrogen Supply Chain” Project

Ammonia Cracking Plant (3D Rendering)TOKYO, October 30, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) and NIPPON SHOKUBAI CO., LTD. (Nippon Shokubai) have received approval for their jointly submitted proposal to Japan's New Energy and Industrial Technology Development Organization (NEDO) for its "Development of Technologies for…

MHI Thermal Systems Launches Two New Models of Air-to-Water Heat Pumps Using Natural Refrigerant R290 for European Market

Hydrolution EZY SeriesTOKYO, October 30, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries Thermal Systems, Ltd. (MHI Thermal Systems), a part of Mitsubishi Heavy Industries (MHI) Group, has added two new models to its "Hydrolution EZY" series of air-to-water (ATW) heat pumps for the European market that utilize…

Hitachi Energy and Blackstone Energy Transition Partners enter strategic partnership to create leading energy service provider in North America

Zurich and New York, October 30, 2025 - (JCN Newswire via SeaPRwire.com) - Hitachi Energy, a wholly owned subsidiary of Hitachi, Ltd., today announced a strategic partnership with Blackstone Energy Transition Partners (“Blackstone”) to expand and strengthen its Service business, supporting customers in maintaining the reliability and safety of power…

MHI-MS to Conduct Demonstration Testing of Vehicle Transport Robots at Nakagusuku Port in Okinawa

Vehicle transport robotsTOKYO, October 30, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries Machinery Systems (MHI-MS), a part of Mitsubishi Heavy Industries (MHI) Group, will conduct demonstration testing of finished vehicle logistics (FVL) using vehicle transport robots to autonomously move automobiles. Following a proposal adopted for "Testbed Support…

Olympus Introduces NBI+TXI(TM) Observation Mode to the EVIS X1(TM) Endoscopy System CV-1500 Video System Center

TOKYO, Oct 29, 2025 - (JCN Newswire via SeaPRwire.com) - Olympus Corporation (Olympus), a global MedTech company committed to making people’s lives healthier, safer and more fulfilling, today announced the launch of the NBI+TXI™ observation mode, which combines Narrow Band Imaging (NBI™ mode) and Texture and Color Enhancement Imaging (TXI™…

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma

TOKYO and RAHWAY, NJ, Oct. 29, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai (Headquarters: Tokyo, CEO: Haruo Naito) and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) today announced results from that Phase 3 LEAP-012 trial evaluating LENVIMA® (lenvatinib), the…

NEC and the Cambodian Mine Action Center Successfully Predict Landmine-Contaminated Areas in Cambodia Using AI

TOKYO, Japan, October 29, 2025 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701) and the Cambodian Mine Action Center (CMAC, *1), the national institution responsible for landmine clearance activities in Cambodia, with assistance from JICA (*2), conducted a proof-of-concept using AI to predict landmine-contaminated areas. This initiative…

Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

RAHWAY, NJ and TOKYO, October 28, 2025 - (JCN Newswire via SeaPRwire.com) - Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) and Eisai (Headquarters: Tokyo, CEO: Haruo Naito) today announced that the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen…